ArticleDiabetes, obesity & metabolism2025
Survey among adult users of semaglutide for weight loss in Denmark: User characteristics, treatment expectations and experienced effects.
Article in Diabetes, obesity & metabolism, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- A qualitative study exploring experiences about using semaglutide for weight loss in a rural setting in Denmark - 'she is probably on the meds'.Scandinavian journal of primary health care · 2026Article
- Treatment Patterns and Experienced Effects of Semaglutide for Weight Management Among Adult Users in Denmark: A Community Pharmacy-Based Cross-Sectional Survey.Diabetes, obesity & metabolism · 2026Article
- Discontinuation of Semaglutide Therapy for Obesity Management.JAMA network open · 2026Article
- GLP-1 Receptor Agonists in the Rehabilitation of Patients with Heart Failure: Mechanisms, Clinical Evidence, and Future Perspectives.Nutrients · 2026Review
- Real-world semaglutide in obesity cohort: effectiveness, safety and persistence across sex, BMI, and prior GLP-1RA treatment.Frontiers in endocrinology · 2026Article
- Recent Studies on the Effectiveness and Safety of Anti-Obesity Medications: A Scoping Review.Diabetes, metabolic syndrome and obesity : targets and therapy · 2026Review
- Beyond weight loss: predictors of treatment satisfaction and patient-reported outcomes in incretin-based therapies. A cross-sectional study.Frontiers in endocrinology · 2026Article
- Intensive weight loss intervention versus usual care in adults with obesity: a protocol for the LightCARE randomised clinical trial.BMJ open · 2025Article
- Gastrointestinal Symptoms in Obesity Therapy: Mechanisms, Epidemiology, and Management Strategies.Biomedicines · 2025Review
- Semaglutide in the Real World: Attitudes of the Population.Pharmacy (Basel, Switzerland) · 2025Article
- Why do patients with obesity discontinue glucagon-like peptide 1 analogues?Diabetes, obesity & metabolism · 2025Article
- 'This Is My Decision': A Qualitative Study of Individuals' Perspectives on Use of Semaglutide for Weight Loss.Basic & clinical pharmacology & toxicology · 2025Article
- Real-world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP-1RA-based weight-loss therapies.Diabetes, obesity & metabolism · 2025 · on this mapReview
- Survey among adult users of semaglutide for weight loss in Denmark: User characteristics, treatment expectations and experienced effects.Diabetes, obesity & metabolism · 2025Article
- Real-World Off-Label Use of Semaglutide for Weight Reduction: User Behavior, Effectiveness, and Satisfaction.Patient preference and adherence · 2025Article
- Medication Adherence to Semaglutide Once-Weekly Injection Among Type-2 Diabetes Patients in Tabuk, Saudi Arabia - A Cross-Sectional Study.Patient preference and adherence · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsSince the launch of semaglutide for weight loss (Wegovy®, SEMA-WL) in late 2022, there has been a huge increase in new users of SEMA-WL. We explored characteristics, treatment expectations and experienced effectiveness and side effects among Danish adults using SEMA-WL. MATERIALS AND
methodsA questionnaire-based survey was conducted from September to December 2023 across 29 Danish community pharmacies. During a 10-day period, pharmacies invited consecutive individuals aged ≥18 years redeeming a prescription on SEMA-WL to complete an electronic questionnaire.
resultsA total of 1013 individuals were invited to study participation of which 55% (n = 559) accepted. Users of SEMA-WL were primarily female (78%, n = 434) and middle-aged adults (36-65 years; 76%, n = 423), with a median body mass index of 36 (interquartile range [IQR] 32-40) at treatment initiation. Two in three users had personally asked their general practitioner to initiate treatment (70%, n = 393). Four in ten users had not discussed expected treatment duration with their general practitioner (42%, n = 237), almost half (46%, n = 258) expected treatment for a limited time period, while only 11% (n = 64) expected lifelong treatment. Self-reported median weight loss was 5.3% (IQR 3.2-8.5) for users treated for <3 months, 10% (IQR 8.2-14) for 3-5 months of treatment and 17% (IQR 13-21) for those treated for >5 months. More than half of users (59%, n = 330) had experienced side effects, most commonly nausea (35%, n = 193) and constipation (29%, n = 160).
conclusionsThis study provides valuable insights into the characteristics, treatment expectations and effects experienced by Danish adult users of SEMA-WL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.